Evidence map›Paper›PMID 35416615›Full record

ArticleInternational ophthalmology2022

Quality-adjusted life years in macular oedema due to age-related macular degeneration, diabetes and central retinal vein occlusion: the impact of anti-VEGF agents in a tertiary centre in Greece.

Nikolaos T Voutsas, Eleni Papageorgiou, Alexandra Tantou, Vassilis A Dimitriou, Evangelia E Tsironi, Maria Kotoula

Abstract read
PubMed Publisher
In one paragraph

Article in International ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Nikolaos T Voutsas *Department of Ophthalmology, University Hospital of Larissa, Mezourlo Area, 41110, Larissa, Greece. ni_vo17@hotmail.com.ORCID http://orcid.org/0000-0002-2591-9326
Eleni Papageorgiou *Department of Ophthalmology, University Hospital of Larissa, Mezourlo Area, 41110, Larissa, Greece.
Alexandra TantouDepartment of Ophthalmology, University Hospital of Larissa, Mezourlo Area, 41110, Larissa, Greece.
Vassilis A DimitriouDepartment of Mathematics, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Evangelia E TsironiDepartment of Ophthalmology, University Hospital of Larissa, Mezourlo Area, 41110, Larissa, Greece.
Maria KotoulaDepartment of Ophthalmology, University Hospital of Larissa, Mezourlo Area, 41110, Larissa, Greece.
University Hospital of Larissa · GRAristotle University of Thessaloniki · GRUniversity of Thessaly · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNeovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME), and macular oedema due to central retinal vein occlusion (CRVO) are leading causes of vision loss, currently managed with anti-vascular endothelial growth factor injections (anti-VEGF). The aim of this study was to calculate QALYs in patients with nAMD, DME, and CRVO treated with anti-VEGF agents (QALYs MATERIAL AND

methodsThe study included 143 treatment-naive patients with macular oedema due to nAMD (n = 79), DME (n = 57), and CRVO (n = 7), who received anti-VEGF injections as monotherapy according to the Treat-and-Extend (T&E) protocol. The anti-VEGF agents were ranibizumab and aflibercept in equivalent fractions. QALYs where calculated by the formula QALY = Utility Value × Time, where "Time" refers to the follow-up period of the study. For QALYs

resultsMean follow-up time was 1.3 ± 1.2 years in the nAMD group, 1 ± 1.3 years in the DME group, and 0.5 ± 1 years in the CRVO group. There was no statistically significant difference between QALYs DISCUSSION/

conclusionPossible explanations for the lack of significant difference between QALYs - and QALYs + in nAMD, DME, and CRVO groups, may be the short time horizon used in this analysis, the inclusion of data from the better-seeing eye (BSE) and the specific socio-economic, geographical and health care characteristics of this rural Greek area.

Indexed as

Diabetes MellitusDiabetic RetinopathyMacular DegenerationMacular EdemaRetinal Vein OcclusionAngiogenesis InhibitorsBevacizumabGreeceHumansIntravitreal InjectionsQuality-Adjusted Life YearsRanibizumabRecombinant Fusion ProteinsVascular Endothelial Growth Factor AAngiogenesis InhibitorsBevacizumabRanibizumabRecombinant Fusion ProteinsVascular Endothelial Growth Factor AAge-related macular degenerationAnti-vascular endothelial Growth factor (anti-VEGF)Central retinal vein occlusionDiabetic macular oedemaQuality adjusted life years (QALY)

Identifiers

PMID35416615
OpenAlexW4223419113

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.